Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT05987969
Other study ID # Alena App RCT 2023 #1
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date March 20, 2023
Est. completion date June 7, 2023

Study information

Verified date August 2023
Source Aya Technologies Limited
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The present study is a randomised controlled trial that seeks to investigate the efficacy and safety of the Alena app as a treatment for social anxiety disorder.


Description:

This will be a 10-week web-based parallel-group unblinded randomised controlled trial with an 8-week intervention period and a 2-week follow-up post-intervention. Participants will be randomly allocated to receive access to the Alena app or to a wait list control group, in a 1:1 ratio. The Alena app primarily comprises CBT-based therapy for social anxiety based on the Clark and Wells model, as well as cognitive assessments, calming exercises and a community forum.


Recruitment information / eligibility

Status Completed
Enrollment 250
Est. completion date June 7, 2023
Est. primary completion date June 7, 2023
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years and older
Eligibility Inclusion criteria: - Scored over 30 on the SPIN (indicating at least moderate social anxiety) - Aged 18 or over - Fluent in English - Has access to a smartphone (iOS or Android) and the internet - UK resident Exclusion criteria: - Currently receiving therapy for their mental health - Mental health medication has changed (dosage or presence) in the last 8 weeks - Scores over 7 on the AUDIT-C and/or yes on either drug dependence question taken from the DUDIT (indicating drug or alcohol abuse) - Previous experience with the Alena app through prior studies or user testing

Study Design


Intervention

Other:
"Alena" mobile application
This mobile application primarily comprises CBT-based therapy for social anxiety based on the Clark and Wells model, as well as cognitive assessments, calming exercises and a community forum.

Locations

Country Name City State
United Kingdom Aya Technologies Limited London

Sponsors (1)

Lead Sponsor Collaborator
Aya Technologies Limited

Country where clinical trial is conducted

United Kingdom, 

Outcome

Type Measure Description Time frame Safety issue
Primary Change in Social Phobia Inventory (SPIN) The SPIN was designed to assess the full spectrum of symptoms that characterise social anxiety, including fear, avoidance and physiological components. Change from baseline SPIN at 8 weeks
Primary Change in Work and Social Adjustment Scale (WSAS) The WSAS measures the extent to which the respondent's problem impairs their ability to carry out day-to-day activities, such as work, home management and social leisure activities. Change from baseline WSAS at 8 weeks
Secondary Change in Social Phobia Inventory (SPIN) The SPIN was designed to assess the full spectrum of symptoms that characterise social anxiety, including fear, Change from SPIN level at the end of the intervention period at 4 weeks later
Secondary Work and Social Adjustment Scale (WSAS) The WSAS measures the extent to which the respondent's problem impairs their ability to carry out day-to-day At the follow-up point of 4 weeks after the end of the intervention period.
Secondary Serious adverse events Serious adverse events are defined as those that meet the criteria for ISO:14155(A:14) Within the intervention period of 8 weeks
See also
  Status Clinical Trial Phase
Not yet recruiting NCT06274112 - Using TMS to Understand Neural Processes of Social Motivation N/A
Completed NCT02554929 - Treatment of Social Anxiety Disorder and Selective Mutism N/A
Completed NCT00684541 - Interpretation Modification Program for Social Phobia N/A
Completed NCT00684320 - Attention Disengagement Training for Social Phobia N/A
Completed NCT03247075 - Internet-delivered CBT vs Internet-delivered Support and Counseling for Youth With Social Anxiety Disorder - An RCT N/A
Completed NCT02811458 - Clinical Trial of Transdiagnostic Cognitive-Behavior Therapy for Anxiety Disorders N/A
Withdrawn NCT04622930 - Waitlist-Control Trial of Smartphone CBT for Social Anxiety Disorder (SAD) N/A
Active, not recruiting NCT05018312 - Modified Collaborative Assessment VS Standard Assessment on Readiness For Psychotherapy Among Patients With Anxiety N/A
Active, not recruiting NCT05124639 - Clinical Trial of a Group Self-management Support Program for Anxiety Disorders N/A
Completed NCT05858294 - The Safety, Acceptability and Efficacy of Alena N/A
Active, not recruiting NCT05600114 - Cannabidiol (CBD) for the Treatment of Social Anxiety Disorder Phase 2
Not yet recruiting NCT06081348 - Sertraline vs. Placebo in the Treatment of Anxiety in Children and AdoLescents With NeurodevelopMental Disorders Phase 2
Not yet recruiting NCT02924610 - Brief Intervention to Reduce Fear Phase 4
Active, not recruiting NCT02592564 - Brain Plasticity and Cellular Aging After Internet-delivered CBT for Social Anxiety Disorder N/A
Recruiting NCT02305537 - Building an Outcomes Assessment Infrastructure to Assess Anxiety Treatment N/A
Terminated NCT03764644 - Web-based Attention Bias Modification Treatment for Childhood Anxiety Disorders N/A
Unknown status NCT01712321 - Study of Vilazodone to Treat Social Anxiety Disorder N/A
Completed NCT01320800 - CBT for Social Anxiety Disorder Delivered by School Counselors Phase 2
Completed NCT00485615 - An Open Label Trial of Omega 3(o3mega+Joy)in the Treatment of Social Phobia Phase 2
Completed NCT00773162 - Flushing in Social Anxiety Disorder on Seroquel Phase 3